tagline 2004
Addthis
- Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows?
- Cell Therapy aka Therapeutic "Vaccine" Surprise Announcement for World AIDS Day
- Project Inform's IX IRTT: Why the Tap 'n' Drainers Have Always Been Wrong; Plus, a New Theory About MDR HIV
- Dogs and Ponies: Mixed Results (and Lots of Diarrhea) for the Tipranavir Studies; Plus Salvage Study Designs for JNJ/Tibotec's PI and Non-Nuke
- Treble Damages: Vaccine Scientists Struggle to Come to Grips With the Field's "Berlin"
- Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo
- The Irony of Bangkok: How to Get 6 Million Poor People on Antiretroviral Therapy -- and 1 Million Rich People Off
- The Agony of Bangkok: Thai Activist Exhorts Conference Crowd to Stand Firm Against U.S. Patent Regime and "Masks of Fake Concern"
- A Call to Arms: Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms
- TDM, Stat!: More Mixes Nixed By Concentration Preoccupations
- Continuous HAART and the Law of Diminishing Returns: French Researchers Question Benefit of Lifelong Antiretroviral Treatment
- Breaking the Silence, v2: Treatment Advocates Strategize At TAG's 2nd Annual International TB/HIV Workshop
- One Step Forward: Merck Vaccine Moves Forward With Efficacy Trial, While Special Committee Tries to Salvage Thai Study
- Checkmate: French African Study Offers Critical Challenge To Generics Obstructionists
- Stern Words For Pfizer
- Goodnight, Gracie! Quirky PK of BI's Tipranavir May Confine Its Use to Limited Rescue Role
- Public Unhealth: Expert Panel's Decision to Recommend Against Routine HCV Screening Draws Community Ire
- Trust Busting: Abbott, Trimeris/Roche Pricing Decisions Rekindle Old R&D Cost Questions
- Letters to the Editor
- Pharmacy by Fiat: Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation
- Peg Elation: XI CROI, Stage for Results of Three Large HCV Treatment Trials
- Where's My Pipeline? Vicissitudes of Medicine and Marketing Take Toll on Me-Too Line Up
- Fuzeon Fizzles: Bungled T-20 Launch Claims Its First Casualties, as Losses Spread
- Crux as Crock: One Shot Immune-Based Therapy Would Be Patient Dream -- and Pharma's Dread
- Seven (Minus 4, Plus 3) Agents to Fix Your Gaze On
- Shot in the Dark: Against the Odds, Immune-Based Therapies for HIV Slog Along
- Blockbusters Beckon: Proliferation of Polymerase Inhibitors and Other Tales From the HCV Crypt
- Heart of the Matter: To Date, Global Fund Offers Hype and Hope -- But Little Else -- to Majority of Those in Need
- For Thousands of PWHIVs, Scale Up = Death
- World AIDS Day in Bolivia: Activists Interrupt Vice Minister of Health at Inauguration Ceremony
- Holding Court: Activist Meeting With FDA Drugs Division Sets Broad Agenda for Change